Antivitamin K Drugs in Stroke Prevention

ISSN: 1875-6212 (Online)
ISSN: 1570-1611 (Print)

Volume 13, 6 Issues, 2015

Download PDF Flyer

Current Vascular Pharmacology

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 23rd of 60 in Peripheral Vascular Disease
  • 84th of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Dimitri P. Mikhailidis
Academic Head, Department of Clinical Biochemistry
Royal Free Hospital Campus
University College London Medical School
University College London (UCL)
Pond Street
London, NW3 2QG

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.966
5 - Year: 2.960

Antivitamin K Drugs in Stroke Prevention

Current Vascular Pharmacology, 11(6): 817-823.

Author(s): Domenico Di Raimondo, Antonino Tuttolomondo, Carmelo Butta, Benedetto Lucifora, Giuseppe Licata and Antonio Pinto.

Affiliation: Dipartimento Biomedico di Medicina Interna e Specialistica, Università degli Studi di Palermo, Palermo, Italy.


Among the different subtypes of ischaemic strokes, almost 20 % are of cardiac origin. Different are the causes of cardioembolic stroke, but the most common is the atrial fibrillation, a supraventricular arrhythmia.

Appropriate use of antiplatelet drugs and anticoagulants after transient ischaemic attack (TIA) or ischaemic stroke depends on whether the underlying cause is cardioembolic or of presumed arterial origin.

Adequate antiplatelet therapy is recommended for secondary prevention after cerebral ischaemia of presumed arterial origin, whether for patients with TIA and ischaemic stroke of cardiac origin, mainly due to atrial fibrillation. Vitamin K antagonists (VKAs) are highly effective in preventing recurrent ischaemic stroke but have important limitations and are thus underused.

Current guidelines still regard Vitamin K Antagonists at INR 2·0–3·0 to be the standard treatment after cerebral ischaemia of cardiac origin for patients who can tolerate them. In this setting antiplatelet therapy provides an alternative when oral anticoagulation is contraindicated or when patient choice or compliance limits choice of therapy, but is much less effective than VKAs. Recent trial data performed with new anticogulants such as the factor Xa and thrombin inhibitors will need to be taken into account, in order to prevent several of the clinical problems actually related to VKAs use.


Vitamin K antagonists, stroke, prevention, cardiac embolism.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 11
Issue Number: 6
First Page: 817
Last Page: 823
Page Count: 7
DOI: 10.2174/157016111106140128113404

Related Journals

Webmaster Contact: Copyright © 2015 Bentham Science